Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2361 to 2370 of 2733 total matches.

Vismodegib (Erivedge) for Basal Cell Carcinoma

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
stem cells, has been implicated in the development of several human cancers.1 Mutations in the Hh ...
The FDA has approved vismodegib (vis moe deg´ ib; Erivedge – Genentech), the first hedgehog (Hh) pathway inhibitor, for oral treatment of metastatic basal cell cancer, locally advanced basal cell carcinoma that has recurred after surgery, or locally advanced basal cell carcinoma in adults who are not candidates for surgery or radiation.
Med Lett Drugs Ther. 2012 Jul 9;54(1394):53-4 |  Show IntroductionHide Introduction

ReShape and Orbera - Two Gastric Balloon Devices for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Aug 31, 2015  (Issue 1476)
Rechargeable System, are FDA approved for long-term treatment of obesity.1 THE DEVICES — The ReShape Dual ...
The FDA has approved the ReShape Integrated Dual Balloon System (ReShape Medical) and the Orbera Intragastric Balloon System (Apollo Endosurgery) for up to 6 months of use in adults with a BMI of 30-40 who have not been able to maintain weight loss with a weight loss program and, for ReShape, who have at least one obesity-related comorbidity. Both devices have been available in the European Union and elsewhere for years (20 years for Orbera). Three other devices, the LAP-Band, the Realize adjustable gastric band, and the Maestro Rechargeable System, are FDA-approved for long-term...
Med Lett Drugs Ther. 2015 Aug 31;57(1476):122-3 |  Show IntroductionHide Introduction

Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025  (Issue 1723)
4 and 6 (CDK4/6) inhibitor such as palbociclib (Ibrance).1,2 MECHANISM OF ACTION — Datroway ...
The FDA has approved datopotamab deruxtecan (Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2   doi:10.58347/tml.2025.1723e |  Show IntroductionHide Introduction

Upadacitinib (Rinvoq) for Giant Cell Arteritis

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
, ulcerative colitis, and Crohn’s disease.1-4 THE DISORDER — Giant cell arteritis is a systemic large-vessel ...
The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq – Abbvie) has been approved by the FDA for treatment of giant cell arteritis. Upadacitinib was approved earlier for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):114-5   doi:10.58347/tml.2025.1733b |  Show IntroductionHide Introduction

Fat Substitutes

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 1990  (Issue 820)
. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Two new substitutes for fat will soon be available in supermarkets in the USA, not directly, but incorporated into low-fat foods. Simplesse (NutraSweet) has already been approved for use by the US Food and Drug Administration (FDA) and is commercially available in some areas, but only in an ice-cream-like product called Simple Pleasures. Trailblazer (Kraft General Foods) is expected to be approved soon.
Med Lett Drugs Ther. 1990 Jun 15;32(820):57 |  Show IntroductionHide Introduction

Screening for Melanoma

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2011  (Issue 1372)
for melanoma and other skin cancers.1 HIGH-RISK GROUPS — Patients with red hair, fair skin, numerous freckles ...
In the absence of randomized studies demonstrating an impact on mortality, the US Preventive Services Task Force (USPSTF) has found the evidence insufficient to recommend a routine whole-body examination for melanoma and other skin cancers.
Med Lett Drugs Ther. 2011 Sep 5;53(1372):72 |  Show IntroductionHide Introduction

Do Calcium Supplements Increase the Risk of Myocardial Infarction?

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2011  (Issue 1375)
in women with an inadequate dietary intake of calcium.1 The safety of calcium supplements has recently ...
Supplemental calcium is recommended for prevention of postmenopausal osteoporosis in women with an inadequate dietary intake of calcium. The safety of calcium supplements has recently been questioned; patients may ask if they should continue to take them. The source of this concern was the publication of 2 meta-analyses in the British Medical Journal.
Med Lett Drugs Ther. 2011 Oct 17;53(1375):83 |  Show IntroductionHide Introduction

Sitagliptin and Simvastatin (Juvisync)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2011  (Issue 1377)
hemoglobin (A1C) and fasting blood glucose levels.1 DPP-4 inhibitors are generally used as alternatives ...
The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin (Zocor, and others).
Med Lett Drugs Ther. 2011 Nov 14;53(1377):89 |  Show IntroductionHide Introduction

An Imaging Agent for Amyloid

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
. IMAGING — Florbetapir binds to fibrillary -amyloid found in neuritic plaques.1,2 After IV injection ...
The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic plaque density in adults being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Med Lett Drugs Ther. 2012 Jul 9;54(1394):54-5 |  Show IntroductionHide Introduction

In Brief: Warning Against Use of Valproate for Migraine Prevention During Pregnancy

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2013  (Issue 1418)
altogether, if possible, in women of childbearing age.1 VALPROATE — Valproic acid and divalproex sodium ...
The FDA is advising health care professionals not to prescribe valproate sodium (Depacon), valproic acid (Depakene, Stavzor, and generics) or divalproex sodium (Depakote, Depakote ER, and generics) for migraine prevention in pregnant women because a recently published study showed that IQ scores are decreased in children of mothers who took these drugs during pregnancy. The FDA recommends avoiding valproate altogether, if possible, in women of childbearing age.1VALPROATE — Valproic acid and divalproex sodium dissociate to valproate in the GI tract. Valproate is considered the drug of choice...
Med Lett Drugs Ther. 2013 Jun 10;55(1418):45 |  Show IntroductionHide Introduction